Although the early use of recombinant human DNase I (rhDNase I) in the treatment of SLE demonstrated a favourable safety profile, its clinical efficacy was limited; nevertheless, it has been approved for the treatment of cystic fibrosis (CF) (154). This evidence concerns the gene DNASE1 and cystic fibrosis.